Channel openings are necessary but not sufficient for use-dependent block of cardiac Na+ channels by flecainide: Evidence from the analysis of disease-linked mutations

Journal of General Physiology

Volumn 120, Issue 1, 2002, Pages 39-51

  Liu, Huajun ^a   Tateyama, Michihiro ^a   Clancy, Colleen E ^a   Abriel, Hugues ^a   Kass, Robert S ^a  

^a Surgeons of Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE; GENE PRODUCT; PROTEIN SCN5A; PROTEIN SUBUNIT; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; ANTIARRHYTHMIC AGENT; VOLTAGE GATED NA+ CHANNEL NA(V)1.5A; VOLTAGE-GATED NA+ CHANNEL NA(V)1.5A;

ALPHA CHAIN; ARTICLE; BRUGADA SYNDROME; CHANNEL GATING; CONTROLLED STUDY; DEPOLARIZATION; DIAGNOSTIC VALUE; DRUG MECHANISM; ELECTRIC POTENTIAL; EMBRYO; GENE MUTATION; GENETIC LINKAGE; HEART; HUMAN; HUMAN CELL; LONG QT SYNDROME; CELL LINE; DRUG EFFECT; GENETICS; HEART ARRHYTHMIA; HEART MUSCLE; METABOLISM; MUTATION; PHYSIOLOGY;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CELL LINE; FLECAINIDE; HUMAN; LONG QT SYNDROME; MUTATION; MYOCARDIUM; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS;

EID: 0036020181     PISSN: 00221295     EISSN: None     Source Type: Journal    
DOI: 10.1085/jgp.20028558     Document Type: Article

References (49)

1. Novel arrhythmogenic mechanism revealed by a long-qt syndrome mutation in the cardiac na(+) channel
2. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome
3. A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome
4. Lidocaine block of LQT-3 mutant human Na+ channels
5. Novel LQT-3 mutation affects Na+ channel activity through interactions between alpha- and beta1-subunits
6. Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery
7. Lidocaine block of cardiac sodium channels
8. Identification of a new SCN5A mutation associated with the long QT syndrome
9. Effects of flecainide, in patients with new SCN5A mutation: Mutation-specific therapy for long-QT syndrome?
10. A single Na(+) channel mutation causing both long-QT and Brugada syndromes
11. Brugada syndrome
12. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts
13. Long QT syndrome and Brugada syndrome: 2 Aspects of the same disease?
14. Lidocaine induces a slow inactivated state in rat skeletal muscle sodium channels
15. Kinetic analysis of phasic inhibition of neuronal sodium currents by lidocaine and bupivacaine
16. Kinetics of local anesthetic inhibition of neuronal sodium currents, pH and hydrophobicity dependence
17. Secondary structure of the human cardiac Na+ channel C terminus. Evidence for a role of helical structures in modulation of channel inactivation
18. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative
19. Mechanism of lidocaine block of late current in long Q-T mutant Na+ channels
20. Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells
21. Local anesthetics: Hydrophilic and hydrophobic pathways for the drug-receptor reaction
22. The pH-dependent rate of action of local anesthetics on the Node of Ranvier
23. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels
24. A revised view of cardiac sodium channel "blockade" in the long-QT syndrome
25. A molecular basis for the different local anesthetic affinities of resting versus open and inactivated states of the sodium channel
26. Role of the C-terminal domain in inactivation of brain and cardiac sodium channels
27. Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide
28. A structural rearrangement in the sodium channel pore linked to slow inactivation and use dependence
29. The elusive link between LQT3 and Brugada syndrome: The role of flecainide challenge
30. Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel
31. Molecular determinants of state-dependent block of Na+ channels by local anesthetics
32. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels
33. Inherited Brugada and LQT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes
34. Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine
35. Electropharmacology of antiarrhythmic drugs
36. Arrhythmogenic actions of antiarrhythmic drugs
37. Drug associated sodium channels inactivate and reactivate at more negative potentials than drug-free channels
38. Effects of quinidine on the sodium current of ventricular guinea-pig myocytes: Evidence for a drug-associated rested state with altered kinetics
39. The inhibition of sodium currents in myelinated nerve by quaternary, derivatives of lidocaine
40. Fundamental properties of local anesthetics. II. Measured octanol:buffer partition coefficients and pKa values of clinically used drugs
41. Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel
42. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes
43. Enhanced Na(+) channel intermediate inactivation in Brugada syndrome
44. Pharmacological targeting of long QT mutant sodium channels
45. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel
46. Differential interaction of R-mexiletine with the local anesthetic receptor site on brain and heart sodium channel alpha-subunits
47. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: Comparison between quinidine, lidocaine, flecainide, propranolol and sotalol
48. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation
49. Pathophysiologic mechanisms of cardiac arrhythmias